---
title: "Onyx Biotec Ltd (ONYX) — Share Price, Financials & Analysis"
symbol: "ONYX"
company: "Onyx Biotec Ltd"
canonical: "https://tapetide.com/stocks/ONYX"
isin: "INE0WVU01018"
nse_symbol: "ONYX"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 70.26
generated_at: "2026-09-13T19:14:34.294Z"
---

# Onyx Biotec Ltd (ONYX)

Canonical page: https://tapetide.com/stocks/ONYX

## Company

- **NSE Symbol:** ONYX
- **ISIN:** INE0WVU01018
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2024-11-22
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** onyxbiotec.com

## About

Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry 
 Syrup for India and overseas, through a 
B2B business model[1]

## Latest Price

- **Price:** ₹38
- **Change:** -0.75 (-1.94%)
- **Open:** ₹38
- **Day High:** ₹38
- **Day Low:** ₹38
- **Previous Close:** ₹38.75
- **Volume:** 2000
- **As Of:** 2026-09-11T07:22:15+00:00

## Key Fundamentals

Observed at 2026-09-11T04:48:04.588640Z.

- **Market Cap:** ₹70.26 Cr
- **Classification:** SME
- **P/E (reported):** -322.9
- **Book Value:** ₹30.56
- **Price to Book:** 1.27
- **Dividend Yield:** 0%
- **ROE:** 8.91%
- **ROCE:** 12.92%
- **Debt to Equity:** 0.27
- **Revenue (yearly):** ₹69.47 Cr
- **Net Income:** ₹-0.82 Cr
- **EBITDA:** ₹3.4 Cr
- **52-Week High:** ₹50
- **52-Week Low:** ₹24.2
- **RSI (14):** 43.22

## Tapetide Score

- **Score:** 47 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 35.6 (of 4473 scored stocks)
- **Confidence:** 81%
- **Data coverage:** 62%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 33.51 | 9% |
| growth | 54.45 | 9% |
| momentum | 75.68 | 12% |
| ownership | 72.72 | 24% |
| quality | 28.12 | 22% |
| valuation | 43.26 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.
- Company has a low return on equity of 6.49% over last 3 years.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | -6.58% | -27.55% | -85.21% |
| ebitda margin growth | -73.36% | -69.06% | -62.03% |
| net income growth | -116.4% | -122.78% | -124.12% |
| revenue growth | 10.1% | 21% | 9.07% |
| roce | 1.02% | 60.5% | 12.46% |
| roe | -38% | 11.14% | -12.04% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 23.89 | 29.86 | 30.15 | 31.8 | 34.59 | 34.88 |
| Expenses | 20.47 | 24.95 | 24.44 | 27.17 | 33.65 | 32.43 |
| Operating Profit | 3.42 | 4.91 | 5.71 | 4.63 | 0.94 | 2.45 |
| OPM % | 14.32 | 16.44 | 18.94 | 14.56 | 2.72 | 7.02 |
| Other Income | 0.04 | 0.09 | 0.99 | 0.18 | 0.24 | 0.21 |
| Interest | 0.83 | 1.27 | 1.36 | 0.62 | 0.55 | 0.66 |
| Depreciation | 0.73 | 1.14 | 1.53 | 1.51 | 1.56 | 1.49 |
| Profit before tax | 1.9 | 2.59 | 3.81 | 2.68 | -0.93 | 0.51 |
| Tax % | 15.26 | 21.24 | 21.52 | 26.12 | -3.23 | -35.29 |
| Net Profit | 1.6 | 2.03 | 2.99 | 1.97 | -0.9 | 0.69 |
| EPS in Rs | 2.71 | 1.52 | 2.24 | 1.09 | -0.5 | 0.38 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 44.86 | 39.49 | 53.75 | 61.95 | 69.47 |
| Expenses | 39.09 | 34.99 | 45.36 | 51.57 | 66.07 |
| Operating Profit | 5.77 | 4.5 | 8.39 | 10.38 | 3.4 |
| OPM % | 12.86 | 11.4 | 15.61 | 16.76 | 4.89 |
| Other Income | 0.12 | 0.11 | 0.13 | 1.17 | 0.44 |
| Interest | 0.65 | 0.57 | 2.16 | 2.02 | 1.21 |
| Depreciation | 1.45 | 1.49 | 1.87 | 3.05 | 3.05 |
| Profit before tax | 3.79 | 2.55 | 4.49 | 6.48 | -0.42 |
| Tax % | 11.61 | 27.45 | 19.15 | 23.46 | -50 |
| Net Profit | 3.35 | 1.84 | 3.63 | 4.95 | -0.21 |
| EPS in Rs | 5.68 | 3.12 | 2.72 | 2.73 | -0.12 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 5.9 | 5.9 | 13.32 | 18.13 | 18.13 |
| Reserves | 10.47 | 12.3 | 11.97 | 37.49 | 37.28 |
| Borrowings | 12.25 | 29.23 | 30.78 | 12.46 | 15.17 |
| Other Liabilities | 8.22 | 11.3 | 18.07 | 23.17 | 24.57 |
| Total Liabilities | 36.84 | 58.73 | 74.14 | 91.25 | 95.15 |
| Fixed Assets | 17.23 | 42.5 | 43.48 | 40.9 | 39.16 |
| CWIP | 4.02 | 0 | 0 | 0 | 3.68 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 15.59 | 16.23 | 30.66 | 50.35 | 52.31 |
| Total Assets | 36.84 | 58.73 | 74.14 | 91.25 | 95.15 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0.49 | 1.96 | 1.52 | 1.42 | -1.49 |
| Cash from Investing Activity | -5.78 | -22.68 | -3.15 | 0.66 | -4.58 |
| Cash from Financing Activity | 5.2 | 16.43 | 3.09 | 5.07 | 1.5 |
| Net Cash Flow | -0.09 | -4.3 | 1.46 | 7.15 | -4.57 |
| Free Cash Flow | -5.3 | -20.78 | -1.7 | 1.91 | -6.48 |
| CFO/OP | 8 | 44 | 18 | 14 | -44 |

### Ratios

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 68.51 | 46.95 | 104.37 | 119.19 | 144.49 |
| Inventory Days | 41.98 | 109.92 | 92.94 | 150.14 | 99.2 |
| Days Payable | 59.46 | 120.16 | 140.83 | 156.02 | 124.7 |
| Cash Conversion Cycle | 51.03 | 36.71 | 56.48 | 113.32 | 118.98 |
| Working Capital Days | 35.72 | -52.22 | 37.62 | 87.49 | 77.29 |
| ROCE % | — | 8.23 | 12.85 | 12.16 | 1.14 |

## Shareholding Pattern

### Quarterly

| Category | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Promoters | 65.1% | 65.1% | 65.1% |
| FIIs | 5.36% | 1.95% | 1.07% |
| DIIs | 0% | 0% | 2.39% |
| Government | 0% | 0% | 0% |
| Public | 18.97% | 22.64% | 23.15% |
| Others | 10.58% | 10.32% | 8.29% |
| No. of Shareholders | 551 | 640 | 586 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 3 / 5 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 39.08 | Sell |
| EMA (10) | 39.15 | Sell |
| SMA (20) | 41.09 | Sell |
| EMA (20) | 40.29 | Sell |
| SMA (50) | 40.99 | Sell |
| EMA (50) | 40.43 | Sell |
| SMA (100) | 38.36 | Sell |
| EMA (100) | 39.36 | Sell |
| SMA (200) | 36.95 | Buy |
| EMA (200) | 40.33 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 41.18 | Neutral |
| MACD (12,26,9) | -1.12 | Sell |
| Stochastic (14,3,3) | 10.17 | Buy |
| ADX (14) | 17.06 | Neutral |
| Williams %R (14) | -90.91 | Buy |
| ATR (14) | 1.62 | High Volatility |
| ROC (12) | -14.12 | Sell |
| Stoch RSI (14) | 27.12 | Neutral |
| UO (7,14,28) | 44.54 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 8 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.](https://nsearchives.nseindia.com/corporate/ONYX_08072026124833_Intimation_74_5__Onyx.pdf) |
| 8 Jul - Onyx Biotec says corporate governance provisions don’t apply for quarter ended June 30, 2026. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 8 Jul - Onyx Biotec says corporate governance provisions don’t apply for quarter ended June 30, 2026.](https://nsearchives.nseindia.com/corporate/ONYX_08072026130125_Non-Applicability_of_CG.pdf) |
| 7 Sep - 21st AGM on September 28, 2026 via VC/OAVM; e-voting details and annual report dispatched. | [Copy of Newspaper Publication 7 Sep - 21st AGM on September 28, 2026 via VC/OAVM; e-voting details and annual report dispatched.](https://nsearchives.nseindia.com/corporate/ONYX_07092026185021_Newspaper_Advertisement.pdf) |
| 7 May 2026 - Compliance certificate confirms Structured Digital Database for FY2026; 3 events captured, no noncompliance. | [Structural Digital Database 7 May 2026 - Compliance certificate confirms Structured Digital Database for FY2026; 3 events captured, no noncompliance.](https://nsearchives.nseindia.com/corporate/ONYX_07052026183311_SDD_Certificate_Final_.pdf) |
| 7 April 2026 - Regulation 74(5) compliance certificate filed for quarter ended March 31, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 7 April 2026 - Regulation 74(5) compliance certificate filed for quarter ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/ONYX_07042026162328_Intimation_74_5__Onyx.pdf) |
| 7 April 2026 - Promoters disclosed no encumbrance on shares for FY ended March 31, 2026. | [General Updates 7 April 2026 - Promoters disclosed no encumbrance on shares for FY ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/ONYX_07042026162659_Intimation_SAST_Regulation_31_4_.pdf) |
| 7 April 2026 - Onyx Biotec says corporate governance provisions are not applicable for quarter ended March 31, 2026. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 7 April 2026 - Onyx Biotec says corporate governance provisions are not applicable for quarter ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/ONYX_07042026163235_Non-Applicability_of_CG.pdf) |
| 6 January 2026 - Corporate governance provisions not applicable for quarter ended Dec 30, 2025; company listed on NSE EMERGE. | [General Updates 6 January 2026 - Corporate governance provisions not applicable for quarter ended Dec 30, 2025; company listed on NSE EMERGE.](https://nsearchives.nseindia.com/corporate/ONYX_06012026175027_Non-Applicability_CG.pdf) |
| 6 January 2026 - Certificate under Reg 74(5) for quarter/nine months ended Dec 31, 2025; demat confirmations Oct–Dec 2025. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 6 January 2026 - Certificate under Reg 74(5) for quarter/nine months ended Dec 31, 2025; demat confirmations Oct–Dec 2025.](https://nsearchives.nseindia.com/corporate/ONYX_06012026174418_Intimation_74_5_OBL_December25.pdf) |
| 5 Sep - Onyx Biotec published newspaper notice for 21st AGM on 28 September 2026; e-voting from 25-27 September. | [Copy of Newspaper Publication 5 Sep - Onyx Biotec published newspaper notice for 21st AGM on 28 September 2026; e-voting from 25-27 September.](https://nsearchives.nseindia.com/corporate/ONYX_05092026162558_Newspaper_Advertisement.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_31538_ONYX_2025_2026_A_99780299_05092026163231.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28215_ONYX_2024_2025_A_8190524_02092025194712.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:14:34.294Z.